As of now, there are over 10000 pharmaceutical industry enterprises above designated size in China, with a total added value accounting for about 4% of the total industrial added value. The number of new drugs under research has jumped to the second place in the world, and the pharmaceutical supply guarantee capacity is constantly improving. At the 2023 China Pharmaceutical Industry Development Conference held on the 17th, the Ministry of Industry and Information Technology released relevant data. The pharmaceutical industry includes chemical preparations, APIs, traditional Chinese patent medicines and simple preparations, medical devices, etc., which is related to the national economy and the people's livelihood and economic development. China has increased its efforts to promote the development of the pharmaceutical industry, continuously improving its policy system, and promoting the growth of a number of leading enterprises in the pharmaceutical industry, as well as the continuous improvement of their innovation capabilities. According to data from the Ministry of Industry and Information Technology, since the 14th Five Year Plan period, the average annual growth rate of R&D investment in the entire industry has exceeded 20%, and innovative achievements in fields such as innovative drugs and high-end medical devices are constantly emerging. Minister of Industry and Information Technology, Jin Zhuanglong, said at the meeting that the Ministry of Industry and Information Technology will accelerate the construction of a modern pharmaceutical industry system and comprehensively improve the level of supply guarantee. In terms of product research and industrialization, focusing on chemical drugs, traditional Chinese medicine, biopharmaceuticals, and medical devices, we will deepen the implementation of pharmaceutical innovation product industrialization projects and pharmaceutical industrialization technology research projects, accelerate the pace of new product industrialization and marketization, and promote the early listing of innovative products. In promoting the optimization and upgrading of the entire industry chain, we will consolidate and enhance the advantages of raw material drug manufacturing, develop and strengthen the biopharmaceutical industry such as antibody drugs and new vaccines, and promote the industry to accelerate its extension to the high-end of the value chain. Give full play to the leading and driving role of leading enterprises, cultivate more specialized and innovative small and medium-sized enterprises, and create a batch of innovative highlands and high-level industrial clusters. In terms of enhancing the guarantee capacity of key products, we will strengthen the construction of production capacity for key products and improve the pharmaceutical reserve system. Support the development of drug supply guarantee consortia with a focus on basic drugs, children's drugs, emergency rescue drugs, etc. In promoting high-level open cooperation, multinational corporations are encouraged to establish research and development centers and innovative drug production bases in China, and domestic enterprises are supported to introduce advanced foreign technologies and products through cooperative development, technology licensing, and other means. Expand the global market, encourage enterprises to carry out international certification, accelerate the pace of "going global" for vaccines, innovative drugs, high-end formulations, and medical devices, and actively participate in international industry division and cooperation. (New News Agency)